Annette Snejbjerg Bartels
Bioanalytiker
LUKKET: Molecular and Cellular Pharmacology
Jagtvej 160, København Ø
1 - 1 ud af 1Pr. side: 10
- 2013
- Udgivet
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?
Munro, A. F., Bartels, Annette Snejbjerg, Balslev, E., Twelves, C. J., Cameron, D. A., Brünner, N. & Bartlett, J. M., 2013, I: Breast Cancer Research (Online Edition). 15, 2, 8 s., R31.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
ID: 6090964
Flest downloads
-
865
downloads
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer: results from a randomized phase III trial from the Danish breast cancer cooperative group
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Udgivet -
850
downloads
High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Udgivet -
687
downloads
Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Udgivet